1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Research Solutions reported fiscal 2026 net income of $2.8 million, or $0.09 per diluted share, up from $1.3 million, or $0.04, a year earlier, while total revenue fell to $48.3 million from $49.1 million. Fourth-quarter revenue of $12.1 million and net income of $666,000 were both below the prior-year quarter, which included a $1.1 million favorable Scite earnout adjustment, so shareholders see a mixed picture of annual profit growth alongside shrinking sales.
Fiscal 2026 net income was $2.8 million, or $0.09 per diluted share, versus $1.3 million, or $0.04, in fiscal 2025.
Fiscal 2026 total revenue was $48.3 million versus $49.1 million; transaction revenue fell to $27.5 million from $30.1 million.
Fourth-quarter net income was $666,000, or $0.02 per diluted share, versus $2.4 million, which included a $1.1 million Scite earnout adjustment.
B2B ARR rose 14.1% to $16.2 million, and total ARR rose 7.8% to $22.5 million as of June 30, 2026.
8x8 posted an investor presentation on September 9, 2026, with first-quarter fiscal 2027 results and fiscal 2027 guidance given as of August 4, 2026. Revenue rose to a record, but the company's own guidance implies lower non-GAAP operating margin and operating profit for fiscal 2027 than fiscal 2026, and the term loan is due in August 2027.
Q1 fiscal 2027 total revenue of $190M, up 4.9% year over year; GAAP operating margin 2.3% and non-GAAP operating margin 9.9%.
Wealthfront reported fiscal second quarter 2027 results for the period ended July 31, 2026. Revenue rose 1% year-over-year to $91.9 million, but GAAP diluted net income fell 49% to $17.6 million and diluted EPS fell to $0.10 from $0.24, mainly due to higher stock-based compensation tied to awards recognized after the December 2025 IPO. Total Platform Assets grew 12% to $99.0 billion, and the company said it surpassed $100 billion at the end of August.
Total revenue $91.9 million, up 1% from $91.1 million; GAAP net income $17.6 million versus $34.7 million
Stock-based compensation expense $16.4 million versus $1.6 million a year earlier; adjusted EBITDA $38.1 million, down 15%
Total Platform Assets $99.0 billion, up 12%; funded clients 1.51 million, up 14%
Company repurchased 3.3 million shares for approximately $30 million in the quarter
Skillsoft reported second-quarter fiscal 2027 revenue of $98.2 million, down 3% from a year earlier, while its net loss narrowed 17% to $15.0 million. The company lowered its full-year revenue guidance to $380 million-$390 million from $388 million-$406 million, citing pressure in its consumer business, and kept its Adjusted EBITDA and free cash flow guidance unchanged. The Global Knowledge business was sold to Enduring Ventures in July 2026.
Q2 revenue was $98.2 million, down 3% from $101.2 million a year earlier.
Net loss improved to $15.0 million, or $1.67 per share, from $18.0 million, or $2.10 per share.
Full-year fiscal 2027 revenue guidance was cut to $380 million-$390 million; Adjusted EBITDA ($108 million-$116 million) and free cash flow ($14 million-$22 million) guidance were maintained.
Global Knowledge sale to Enduring Ventures was completed in July 2026.
Limoneira reported fiscal third-quarter 2026 revenue of $43.8 million, down from $47.5 million a year earlier, and a net loss of $0.17 per diluted share versus $0.06. Adjusted EBITDA rose to $3.9 million from $3.0 million, and the company raised its avocado volume guidance while narrowing lemon volume to the lower end of its range. The company also agreed to sell the Windfall Farms property for $15.0 million in cash, with closing expected September 14, 2026.
Q3 total net revenues were $43.8 million, versus $47.5 million, mainly due to the transition of citrus brokerage operations to Sunkist.
Q3 operating loss was $3.0 million, versus $0.6 million; net loss per diluted share was $0.17, versus $0.06.
Adjusted EBITDA was $3.9 million, versus $3.0 million in the prior-year quarter.
Fiscal 2026 avocado volume guidance raised to 7.0 to 7.25 million pounds; lemon volume expected at the lower end of 4.0 to 4.5 million cartons.
On September 7, 2026, Lexaria Bioscience Corp. agreed with holders of existing warrants covering 453,969 shares to exercise them immediately at a reduced $12.92 per share, for expected gross proceeds of about $5.9 million before fees and expenses. In return, the company will issue new unregistered Series A and Series B warrants, each covering 453,969 shares at $12.67, and must file a resale registration statement for the underlying shares. The cash is intended for working capital and general corporate purposes, but the reduced exercise price and new warrants add potential future share issuance for existing shareholders.
Expected gross proceeds of about $5.9 million from the warrant exercises, before placement agent fees and offering expenses; closing expected September 9, 2026.
Existing warrants issued in 2024 and 2025 had original exercise prices from $17.85 to $45.90 per share; holders exercised at $12.92.
New Series A warrants (five-year term) and Series B warrants (18-month term) each cover 453,969 shares at $12.67 per share.
H.C. Wainwright & Co. is placement agent, paid a fee of 7% of gross proceeds, and received warrants for 15,889 shares at $16.15.
electroCore's board appointed Joshua Lev, its interim president and CFO, and Mike Fox, its COO, as co-Chief Executive Officers and president, effective September 8, 2026. Both will keep their current finance and operations roles and join the board as Class III directors, increasing the board from six to eight members. The filing also shows higher pay for both executives, a revised executive severance policy, and bylaw changes that tighten rules for shareholder director nominations.
Lev and Fox were named co-CEOs and president on September 8, 2026, and will remain CFO and COO, respectively.
Lev's base salary rises from $470,000 to $540,000 with a 50% target bonus; Fox's base salary rises from $505,000 to $540,000 and his target bonus rises from 40% to 50%.
Each received 55,000 restricted stock units vesting in equal annual installments over three years.
The CEO change-in-control severance formula now provides a lump sum at a 1.5x multiple, and the bylaws add stricter advance notice and group disclosure requirements for shareholder nominees.
Nasdaq granted Iveda Solutions an additional 180 calendar days, until March 1, 2027, to regain compliance with its $1.00 minimum bid price rule, after the company requested the extension on September 2, 2026. The extension delays a possible delisting, but the stock must still close at or above $1.00 for at least 10 consecutive business days, and the company has not decided on a reverse stock split.
Nasdaq first notified Iveda on March 6, 2026, that its closing bid price had been below $1.00 for 30 consecutive business days.
Iveda received the second grace period letter from Nasdaq on September 4, 2026, extending the deadline to March 1, 2027.
Iveda may consider a reverse stock split if appropriate, but has not announced a decision to implement one.
The company may still be delisted during the period if it fails other Nasdaq listing requirements, and Nasdaq would issue a delisting notice if compliance is not shown by March 1, 2027.
Tenax Therapeutics furnished an investor presentation at the Cantor Global Healthcare Conference on September 9, 2026, reviewing full results of its Phase 3 LEVEL trial of TNX-103 (oral levosimendan) in PH-HFpEF. The trial did not reach statistical significance on its primary endpoint, the change in 6-minute walk distance, which was a 3.5-meter treatment difference (p = 0.63). The company says the results will guide the design of its follow-on trial, LEVEL-2, and the presentation includes subgroup results for patients with baseline walk distance below the median.
Primary endpoint, 6MWD change at week 12: 3.5 m treatment difference vs. placebo (p = 0.63); the company describes the trial as not meeting its primary endpoint.
Overall population NT-proBNP fell 49% vs. placebo at week 12 (nominal p < 0.0001); RVSP fell 3.5 mmHg vs. placebo.
Prespecified subgroup with baseline 6MWD below 333 m: +26.3 m treatment effect (95% CI 6.0 to 46.7; nominal p = 0.0112); these are subgroup results from a trial whose primary endpoint was not met.
Adverse events were higher on TNX-103 (86.7% vs. 71.9% any adverse event); serious adverse events were 10.8% vs. 10.7%.
LSB Industries furnished a September 2026 investor presentation under Regulation FD, which it may use in meetings with investors and analysts. The deck shows trailing twelve-month net sales of $658 million, up 22% from a year earlier, and adjusted EBITDA of $199 million, up 63%, though the company reported a net loss of $6.2 million for the quarter ended June 30, 2026, compared with net income of $3.0 million a year earlier.
Q2 2026 trailing twelve-month net sales of $658 million, up 22% year over year; adjusted EBITDA of $199 million, up 63%
Three months ended June 30, 2026: net loss of $6.2 million versus net income of $3.0 million a year earlier; turnaround costs of $28.8 million
Net leverage ratio of 1.1x as of June 30, 2026, versus 2.8x a year earlier; El Dorado carbon capture project expected to begin operations in Q1 2027 and add $25 million to $30 million of annual earnings once fully operational
Pyxis Oncology (Nasdaq: PYXS) reported updated Phase 1 monotherapy data for micvotabart pelidotin (MICVO) in second-line and beyond recurrent or metastatic head and neck squamous cell carcinoma, with a data cutoff of August 18, 2026. The company reported a 36% confirmed objective response rate among 33 efficacy-evaluable patients and said no new safety signals were observed, but 54.3% of the 35 safety-evaluable patients had treatment-related adverse events of grade 3 or higher. The company plans to initiate a pivotal Phase 3 study in mid-2027.
Confirmed objective response rate of 36% (12 of 33) and disease control rate of 94% (31 of 33)
Median progression-free survival of 6.2 months; 12-month overall survival probability of 79%; median overall survival not yet reached
Grade 3 or higher treatment-related adverse events in 54.3% of patients (19 of 35); 5 patients (14.3%) discontinued treatment due to these events
End of Phase 2 meeting with the FDA expected in the first quarter of 2027; Phase 3 Headliner trial planned to start in mid-2027
Destination XL Group reported second-quarter fiscal 2026 sales of $111.6 million, down 3.4% from a year earlier, with comparable sales down 3.5%. Net income was $2.0 million, or $0.04 per diluted share, helped by a $4.6 million tariff refund, compared with a prior-year net loss of $0.3 million. The company also said its board no longer considers the proposed FullBeauty merger advisable and recommends that stockholders vote against the share issuance proposal.
Total sales $111.6 million vs. $115.5 million a year earlier; comparable sales down 3.5%, with stores down 4.3% and direct down 1.6%.
Net income $2.0 million, or $0.04 per diluted share, including a $4.6 million tariff refund; prior-year quarter was a net loss of $0.3 million.
Board determined the FullBeauty merger is no longer advisable and recommends stockholders vote against the issuance proposal.
Cash and investments were $20.1 million at August 1, 2026, with no outstanding debt.
SailPoint reported fiscal second quarter 2027 results for the period ended July 31, 2026, with total revenue up 17% year-over-year to $309 million and total ARR up 25% to $1.231 billion. The GAAP operating loss widened to $59 million from $41 million a year earlier, while adjusted income from operations rose to $63 million from $54 million. The company also gave fiscal 2027 revenue guidance of $1,265 million to $1,275 million and adjusted EPS guidance of $0.30 to $0.34.
Total revenue was $309 million, up 17% year-over-year; subscription revenue was $295 million, up 19%.
GAAP operating loss was $(59) million, or (19)% of revenue, versus $(41) million, or (15)%, in fiscal Q2 2026.
Adjusted income from operations was $63 million, or 20% of revenue, versus $54 million, or 20%, a year earlier.
Fiscal 2027 guidance: total revenue $1,265 million to $1,275 million; adjusted EPS $0.30 to $0.34; Q3 revenue $326 million to $330 million.
Independence Realty Trust (IRT) signed a merger agreement with Centerspace (CSR) on September 8, 2026, in an all-stock deal under which Centerspace holders receive 3.800 IRT shares per share. IRT holders would own about 78% of the combined company and Centerspace holders about 22%, on a fully diluted basis excluding preferred units. The deal requires approval from both companies' shareholders and is expected to close as early as the end of the fourth quarter of 2026.
Exchange ratio: 3.800 IRT common shares for each Centerspace common share, with about 67.6 million IRT shares and common units to be issued
Pro forma ownership: IRT holders about 78%, Centerspace holders about 22%; combined enterprise value about $8.1 billion
IRT expects approximately 5% accretion to 2027 Core FFO per share and about $24 million of annualized synergies
Closing expected as early as the end of Q4 2026, subject to shareholder approvals and lender consents
Jersey Mike's reported second-quarter 2026 results for the 13 weeks ended June 28, 2026, with total revenue up 10% year over year to $208 million and same-store sales up 2.3%. Net income fell to $37 million from $59 million, while Adjusted EBITDA rose 7% to $114 million. The company also gave full-year 2026 guidance, which for shareholders sets targets for same-store sales, store growth and Adjusted EBITDA.
Total revenue rose 10% to $208 million; systemwide sales rose 10% to $1.210 billion
Net income was $37 million versus $59 million a year earlier, including a $14 million gain on sale of company-owned stores
Adjusted EBITDA rose 7% to $114 million, including a $10 million net adverse impact from advertising fund timing
Full-year 2026 outlook: same-store sales growth of 2.5-3.0%, net unit growth of at least 8%, Adjusted EBITDA growth of at least 20%
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.